Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings. [PDF]
Neural Regen Res, 2023 Type-B monoamine oxidase inhibitors, encompassing selegiline, rasagiline, and safinamide, are available to treat Parkinson's disease. These drugs ameliorate motor symptoms and improve motor fluctuation in the advanced stages of the disease. There is also
Alborghetti M +5 more
europepmc +4 more sources
Monoamine Oxidase Inhibitors [PDF]
Anaesthesia, 1964 Publisher Summary This chapter describes the various classes of chemical compounds, which have an inhibitory action on monoamine oxidase (MAO). The chapter discusses the current theories of the function of monoamine oxidase and the possible mechanism by which the MAO inhibitors (MAOI) react with MAO.
Gerald Garmany, R.R.P. Warner
+16 more sources
Moving on With Monoamine Oxidase Inhibitors.
Focus (Am Psychiatr Publ), 2021 Bodkin JA, Dunlop BW.
europepmc +4 more sources
N-methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor [PDF]
, 2014 On the basis of N-((5-(3-(1-benzylpiperidin-4-yl)propoxy)-1-methyl-1H-indol-2-yl)methyl)-N-methylprop-2-yn-1-amine (II, ASS234) and QSAR predictions, in this work we have designed, synthesized, and evaluated a number of new indole derivatives from which ...
Agbaba, D. +13 more
core +3 more sources
(E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors [PDF]
, 2016 A series of (E)-3-heteroarylidenechroman-4-ones (1a-r) was designed, synthesized and investigated in vitro for their ability to inhibit the enzymatic activity of both human monoamine oxidase (hMAO) isoforms, hMAO-A and hMAO-B.
Alcaro, Stefano +6 more
core +1 more source
Benzo[b]tiophen-3-ol derivatives as effective inhibitors of human monoamine oxidase: design, synthesis, and biological activity [PDF]
, 2019 A series of benzo[b]thiophen-3-ols were synthesised and investigated as potential human monoamine oxidase (hMAO) inhibitors in vitro as well as ex vivo in rat cortex synaptosomes by means of evaluation of 3,4-dihydroxyphenylacetic acid/dopamine (DOPAC/DA)
Alcaro, Stefano +13 more
core +1 more source
Reactive oxygen-related diseases: therapeutic targets and emerging clinical indications [PDF]
, 2015 SIGNIFICANCE Enhanced levels of reactive oxygen species (ROS) have been associated with different disease states. Most attempts to validate and exploit these associations by chronic antioxidant therapies have provided disappointing results. Hence, the
Ana I. Casas +21 more
core +2 more sources
Design, synthesis, docking studies and monoamine oxidase inhibition of a small library of 1-acetyl- and 1-thiocarbamoyl-3,5-diphenyl-4,5-dihydro-(1h)-pyrazoles [PDF]
, 2019 New N-acetyl/N-thiocarbamoylpyrazoline derivatives were designed and synthesized in high yields to assess their inhibitory activity and selectivity against human monoamine oxidase A and B.
Carradori, Simone +8 more
core +1 more source
Pharmacology and clinical drug candidates in redox medicine [PDF]
, 2015 SIGNIFICANCE Oxidative stress is suggested to be a disease mechanism common to a wide range of disorders affecting human health. However, so far, the pharmacotherapeutic exploitation of this, for example, based on chemical scavenging of pro-oxidant ...
Casas, Ana I +11 more
core +2 more sources
Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells [PDF]
, 2007 Monoamine oxidases (MAOs) are mitochondrial enzymes which control the levels of neurotransmitters in the brain and dietary amines in peripheral tissues via oxidative deamination. MAO has also been implicated in cell signalling. In this study, we describe
Billett E. E. +7 more
core +1 more source